Key Takeaways:
Investors in Regencell Bioscience Holdings Limited (NASDAQ: RGC) have until June 23, 2026, to file for lead plaintiff status in a securities fraud lawsuit following an 18.56% stock decline.
"Regencell suffered from vulnerability to market manipulation," according to the complaint filed by The Schall Law Firm, which alleges the company’s public statements were "false and materially misleading throughout the class period."
The lawsuit covers investors who purchased RGC securities between October 28, 2024, and October 31, 2025. The legal action follows a company disclosure on Oct. 31, 2025, that it had received a subpoena from the U.S. Department of Justice. On the news, the stock fell $3.09 to close at $13.56 on November 3, 2025.
The core of the lawsuit claims Regencell failed to disclose its susceptibility to market manipulation, which exposed investors to significant risk and led to a DOJ investigation into the trading of its shares, potentially resulting in fines and legal costs.
Several national shareholder rights litigation firms, including Glancy Prongay Wolke & Rotter LLP and Rosen Law Firm, have issued reminders to investors about the upcoming deadline. The complaints allege that the company did not reveal that the volatility in its share price subjected it to heightened regulatory scrutiny and potential reputational and financial harm.
According to the filings, defendants' positive statements about Regencell's business and prospects lacked a reasonable basis. The company stated it expects to incur significant legal costs in connection with responding to the DOJ investigation.
The string of lawsuits places significant legal and financial pressure on the company. The stock's sharp decline has brought its price to a multi-month low, and investors will now watch for the company's formal response to the litigation and any further disclosures regarding the DOJ investigation.
This article is for informational purposes only and does not constitute investment advice.
